A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04214470 |
Recruitment Status :
Recruiting
First Posted : January 2, 2020
Last Update Posted : September 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Irritable Bowel Irritable Bowel Syndrome Irritable Bowel Syndrome With Diarrhea Irritable Bowel Syndrome Mixed Irritable Bowel Syndrome With Constipation Irritable Bowel Syndrome Without Diarrhea Irritable Bowel Syndrome Aggravated Irritable Bowel Syndrome Characterized by Constipation Irritable Bowel Syndrome Characterised by Alternating Bowel Habit | Other: No intervention |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Irritable Bowel Syndrome |
Actual Study Start Date : | March 2, 2020 |
Estimated Primary Completion Date : | March 2023 |
Estimated Study Completion Date : | July 2023 |
Group/Cohort | Intervention/treatment |
---|---|
Irritable Bowel Syndrome Patients
Patients with IBS.
|
Other: No intervention
There is no intervention for this study |
- Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing [ Time Frame: Three years ]Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with diabetes mellitus
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent
- Male or female of all ages
- Diagnosis of IBS
Exclusion Criteria:
- Refusal to sign informed consent form
- History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
- Postoperative stoma, ostomy, or ileoanal pouch
- Participation in any experimental drug protocol within the past 12 weeks
- Treatment with total parenteral nutrition

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04214470
Contact: Sabine Hazan, MD | 18053390549 | drsabinehazan@progenabiome.com | |
Contact: Jordan Daniels, MS | 18053390549 | jordan@progenabiome.com |
United States, California | |
ProgenaBiome | Recruiting |
Ventura, California, United States, 93003 | |
Contact: Sabine Hazan, MD 805-339-0549 drsabinehazan@progenabiome.com | |
Contact: Jordan Daniels, MS 805-339-0549 jordan@progenabiome.com | |
Principal Investigator: Sabine Hazan, MD |
Principal Investigator: | Sabine Hazan | ProgenaBiome |
Responsible Party: | ProgenaBiome |
ClinicalTrials.gov Identifier: | NCT04214470 |
Other Study ID Numbers: |
PRG-036 |
First Posted: | January 2, 2020 Key Record Dates |
Last Update Posted: | September 5, 2021 |
Last Verified: | September 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan to share IPD. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Irritable Bowel Syndrome Syndrome Constipation Diarrhea Disease Pathologic Processes |
Signs and Symptoms, Digestive Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |